Key result
Empagliflozin significantly improved endothelial function, with median flow-mediated dilatation increasing from 3.5% to 4.7%, in diabetic patients with coronary artery disease.
Why the study?
The mechanisms underlying the cardiovascular benefits of SGLT2 inhibitors have not been fully clarified.
Does empagliflozin 10 mg/d improve endothelial function and metabolic parameters in diabetic patients with coronary artery disease?
Population
50 diabetic patients with established CAD
Comparison
Empagliflozin 10 mg/d evaluated before and after treatment
Follow-up
Six months
Authors
Loading...
TG reduction may link empagliflozin to endothelial recovery in diabetic CAD; leaves open causal role in CV outcomes.
Observational (n=50)
Open-label
No
Does empagliflozin 10 mg/d improve endothelial function and metabolic parameters in diabetic patients with coronary artery disease?
Absolute Event Rate: 4.7% vs 3.5%
p-value: p=0.001
Empagliflozin improves endothelial function in diabetic patients with CAD, a benefit that appears strongly associated with reductions in plasma triglycerides.
Sawada et al. (2019) conducted an observational in Type 2 diabetes mellitus with coronary artery disease (n=50). Empagliflozin vs. Baseline (single-arm) was evaluated on Change in % flow-mediated dilatation (%FMD) (p=0.001). Empagliflozin significantly improved endothelial function, with median flow-mediated dilatation increasing from 3.5% to 4.7%, in diabetic patients with coronary artery disease.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: